Lonza expands services in China
This article was originally published in Scrip
The contract pharmaceuticals and chemicals manufacturer Lonzahas set up a new business unit in China to provide a range of engineering, facility design and maintenance services. The operation would initially service the life sciences sector in the country but might eventually expand to the other markets, the Swiss firm said. Lonza opened a small-scale synthesis facility in China last year as part of a continued build-up in the country.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.